Gufic Biosciences Limited (IN:GUFICBIO)
:GUFICBIO
Want to see IN:GUFICBIO full AI Analyst Report?
GUFICBIO Stock Chart & Stats
₹338.15
-₹9.05(-1.92%)
At close: 4:00 PM EST
₹338.15
-₹9.05(-1.92%)
Day’s Range― - ―
52-Week Range₹267.50 - ₹409.00
Previous CloseN/A
Volume28.80K
Average Volume (3M)2.36K
Market Cap
₹27.97B
Enterprise Value₹31.64B
Total Cash (Recent Filing)₹880.79M
Total Debt (Recent Filing)₹3.69B
Price to Earnings (P/E)67.8
Beta0.76
Next Earnings
May 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.03%
Share Statistics
EPS (TTM)5.68
Shares Outstanding100,282,510
10 Day Avg. Volume2,111
30 Day Avg. Volume2,356
Financial Highlights & Ratios
PEG Ratio-2.39
Price to Book (P/B)5.63
Price to Sales (P/S)4.13
P/FCF Ratio124.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth across years signals expanding market penetration in branded and generic medicines. Steady revenue expansion supports operating leverage, funds reinvestment in sterile injectable and lyophilized capacity, and underpins medium-term cash generation potential.
Margin SustainabilityDurable gross and EBIT margins reflect structural cost control in manufacturing and product mix advantages. Persistent margin strength provides a cushion against pricing pressure in generics, enabling internal funding of capex and R&D and supporting sustainable profitability over multiple quarters.
Stable Equity BaseA growing equity base and healthy equity ratio enhance financial flexibility for strategic investments and resilience to shocks. Strong shareholder equity reduces reliance on short-term debt, supports long-term solvency and gives management scope to pursue capacity expansion or acquisitions responsibly.
Bears Say
Cash Flow VolatilityIrregular free cash flow and weak conversion of earnings into cash limit the company's ability to self-fund growth or reliably service debt. This variability increases reliance on external financing in capex cycles and raises execution risk for multi-quarter investments.
Elevated LeverageModerate to high leverage amplifies financial risk during revenue or margin slowdowns. Debt servicing can constrain capital allocation, reduce strategic optionality and increase refinancing risk, especially given the company's cash flow variability and cyclical pharma dynamics.
Net Income VolatilityFluctuating net margins point to inconsistent bottom-line performance from pricing, one-offs or cost swings. Persistent volatility complicates forecasting, undermines confidence in earnings durability, and can hinder disciplined reinvestment and long-term stakeholder planning.
Gufic Biosciences Limited News
GUFICBIO FAQ
What was Gufic Biosciences Limited’s price range in the past 12 months?
Gufic Biosciences Limited lowest stock price was ₹267.50 and its highest was ₹409.00 in the past 12 months.
What is Gufic Biosciences Limited’s market cap?
Gufic Biosciences Limited’s market cap is ₹27.97B.
When is Gufic Biosciences Limited’s upcoming earnings report date?
Gufic Biosciences Limited’s upcoming earnings report date is May 29, 2026 which is in 9 days.
How were Gufic Biosciences Limited’s earnings last quarter?
Gufic Biosciences Limited released its earnings results on Feb 13, 2026. The company reported ₹1.239 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.239.
Is Gufic Biosciences Limited overvalued?
According to Wall Street analysts Gufic Biosciences Limited’s price is currently Overvalued.
Does Gufic Biosciences Limited pay dividends?
Gufic Biosciences Limited pays a Annually dividend of ₹0.1 which represents an annual dividend yield of 0.03%. See more information on Gufic Biosciences Limited dividends here
What is Gufic Biosciences Limited’s EPS estimate?
Gufic Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gufic Biosciences Limited have?
Gufic Biosciences Limited has 100,282,510 shares outstanding.
What happened to Gufic Biosciences Limited’s price movement after its last earnings report?
Gufic Biosciences Limited reported an EPS of ₹1.239 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.022%.
Which hedge fund is a major shareholder of Gufic Biosciences Limited?
Currently, no hedge funds are holding shares in IN:GUFICBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gufic Biosciences Limited
Gufic Biosciences Limited engages in manufacture and marketing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, it offers spark, criti care, and ferticare pharmaceutical products; and herbal and personal care products. The company supplies its products to hospital chains and medical facilities. It also exports its products to more than 20 countries. The company was founded in 1970 and is based in Mumbai, India.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―